Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme

David M. Peereboom; Dale R. Shepard; Manmeet S. Ahluwalia; Cathy J. Brewer; Neeraj Agarwal; Glen H. J. Stevens; John H. Suh; Steven A. Toms; Michael A. Vogelbaum; Robert J. Weil; Paul Elson; Gene H. Barnett

doi:10.1007/S11060-009-0067-2

Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme

David M. Peereboom, Dale R. Shepard, Manmeet S. Ahluwalia, Cathy J. Brewer, Neeraj Agarwal, Glen H. J. Stevens, John H. Suh, Steven A. Toms, Michael A. Vogelbaum, Robert J. Weil, Paul Elson, Gene H. Barnett

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of neuro-oncology
Volume	98
DOIs	https://doi.org/10.1007/S11060-009-0067-2
State	Published - May 1 2010

Disciplines

Medicine and Health Sciences
Gastroenterology
Surgery
Internal Medicine

Access to Document

10.1007/S11060-009-0067-2License: Unspecified

Cite this

Peereboom, D. M., Shepard, D. R., Ahluwalia, M. S., Brewer, C. J., Agarwal, N., Stevens, G. H. J., Suh, J. H., Toms, S. A., Vogelbaum, M. A., Weil, R. J., Elson, P., & Barnett, G. H. (2010). Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. Journal of neuro-oncology, 98. https://doi.org/10.1007/S11060-009-0067-2

@article{425e0223964548c0abe2ac0bf767d6c3,

title = "Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme",

author = "Peereboom, \{David M.\} and Shepard, \{Dale R.\} and Ahluwalia, \{Manmeet S.\} and Brewer, \{Cathy J.\} and Neeraj Agarwal and Stevens, \{Glen H. J.\} and Suh, \{John H.\} and Toms, \{Steven A.\} and Vogelbaum, \{Michael A.\} and Weil, \{Robert J.\} and Paul Elson and Barnett, \{Gene H.\}",

note = "Approximately 40-50\% of glioblastomas (GBM) overexpress epidermal growth factor receptor (EGFR). Erlotinib is a specific and potent EGFR tyrosine kinase inhibitor active against refractory GBM. Patients with non-small cell lung cancer and ≥grade 2 erlotinib-induced rash have improved survival.",

year = "2010",

month = may,

day = "1",

doi = "10.1007/S11060-009-0067-2",

language = "American English",

volume = "98",

journal = "Journal of neuro-oncology",

}

TY - JOUR

T1 - Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme

AU - Peereboom, David M.

AU - Shepard, Dale R.

AU - Ahluwalia, Manmeet S.

AU - Brewer, Cathy J.

AU - Agarwal, Neeraj

AU - Stevens, Glen H. J.

AU - Suh, John H.

AU - Toms, Steven A.

AU - Vogelbaum, Michael A.

AU - Weil, Robert J.

AU - Elson, Paul

AU - Barnett, Gene H.

N1 - Approximately 40-50% of glioblastomas (GBM) overexpress epidermal growth factor receptor (EGFR). Erlotinib is a specific and potent EGFR tyrosine kinase inhibitor active against refractory GBM. Patients with non-small cell lung cancer and ≥grade 2 erlotinib-induced rash have improved survival.

PY - 2010/5/1

Y1 - 2010/5/1

UR - https://link.springer.com/10.1007/s11060-009-0067-2

U2 - 10.1007/S11060-009-0067-2

DO - 10.1007/S11060-009-0067-2

M3 - Article

VL - 98

JO - Journal of neuro-oncology

JF - Journal of neuro-oncology

ER -

Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme

Disciplines

Access to Document

Other files and links

Cite this